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A B S T R A C T
Purpose
Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete
response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic
disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and
lapatinib added to paclitaxel, considering tumor and microenvironment molecular features.
Patients and Methods
Patientswith stage II to III HER2-positive breast cancer underwent tumor biopsy followed by random
assignment to paclitaxel plus trastuzumab alone (TH) or with the addition of lapatinib (THL) for
16 weeks before surgery. An investigational arm of paclitaxel plus lapatinib (TL) was closed early.
The primary end point was pCR in the breast; correlative end points focused on molecular features
identified by gene expression–based assays.
Results
Among 305 randomly assigned patients (THL, n 5 118; TH, n 5 120; TL, n 5 67), the pCR rate was
56% (95% CI, 47% to 65%) with THL and 46% (95% CI, 37% to 55%) with TH (P 5 .13), with no
effect of dual therapy in the hormone receptor–positive subset but a significant increase in pCRwith
dual therapy in those with hormone receptor–negative disease (P 5 .01). The tumors were
molecularly heterogeneous by gene expression analysis using mRNA sequencing (mRNAseq). pCR
rates significantly differed by intrinsic subtype (HER2 enriched, 70%; luminal A, 34%; luminal B,
36%; P , .001). In multivariable analysis treatment arm, intrinsic subtype, HER2 amplicon gene
expression, p53 mutation signature, and immune cell signatures were independently associated
with pCR. Post-treatment residual disease was largely luminal A (69%).
Conclusion
pCR to dual HER2-targeted therapy was not significantly higher than single HER2 targeting. Tissue
analysis demonstrated a high degree of intertumoral heterogeneity with respect to both tumor
genomics and tumor microenvironment that significantly affected pCR rates. These factors should
be considered when interpreting and designing trials in HER2-positive disease.
J Clin Oncol 34:542-549. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Untreated human epidermal growth factor receptor
2 (HER2) –positive disease is the most aggressive
breast cancer phenotype, but its prognosis has been
transformed by HER2-targeting drugs. The anti-
HER2 monoclonal antibody trastuzumab has
reduced mortality in stage I to III disease by 37%
when combinedwith adjuvant chemotherapy.1Other
HER2-targeting drugs approved for metastatic disease
include the small-molecule inhibitor lapatinib, the
anti-HER2 heterodimerization domain antibody
pertuzumab, and the antibody–drug conjugate tras-
tuzumab emtansine. In patients with metastatic
HER2-positive disease, the use of two HER2-targeted
drugs (pertuzumab and trastuzumab administered
with chemotherapy v trastuzumab alone2 or lapatinib
and trastuzumab v lapatinib alone3) has improved
survival.
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Neoadjuvant (preoperative) trials deliver a potential surrogate
end point (pathologic complete response [pCR]); such trials are
proposed as guides in the design of adjuvant trials and, more recently,
as bases for accelerated drug approval.4 In randomized neoadjuvant
trials, dual HER2 targeting generally results in higher pCR rates, but
the magnitude of this effect has varied.5-7 However, the extent to
which an increase in pCR will improve overall outcomes remains
uncertain; a recent large adjuvant trial of dual targeting with tras-
tuzumab and lapatinib reported a nonsignificant 16% lower relapse
rate in the dual targeting arm8 and no impact on overall survival.
In addition to treatment, several biologic features are implicated
in response heterogeneity to HER2 targeting, including tumor
intrinsic subtype,9 hormone receptor status,5,6,9,10 alterations in
signaling pathways such as phosphatidylinositol 3-kinase (PI3K) and
HER family members, estrogen receptor pathways,10-14 and host
factors such as antitumor immune response.15,16 Recent advances in
molecular biology allow practical assessments of these newly defined
and evolving subtypes of cancer, and this may informmore efficient
drug development as we pursue the practical deployment of pre-
cision medicine.
Cancer and Leukemia Group B (CALGB) 40601was a three-arm
randomized phase III trial in operable HER2-positive breast cancer of
preoperative chemotherapy comparing paclitaxel with the addition of
trastuzumab alone or lapatinib alone or dual HER2 blockade with
both drugs. Dedicated research biopsies were obtained from all
participants before initiation of therapy and permitted simultaneous
examination of drug effect, the impact of tumor and host factors on
response to therapy, and molecular profile of residual disease.
PATIENTS AND METHODS
Study Design and Patients
Patients eligible for CALGB 40601 had newly diagnosed, histologically
confirmed, untreated clinical stage II to III HER2-positive disease. HER2
positivity was determined locally by immunohistochemistry or fluorescence
in situ hybridization according to American Society of Clinical Oncology/
College of American Pathology guidelines.17 Patients were age$ 18 years, had
tumors $ 1 cm in size, and had a pretreatment left ventricular ejection
fraction $ 50%. Patients with multicentric or bilateral disease were eligible if
the target lesion met other eligibility criteria. Each participant signed an
institutional review board–approved, protocol-specific informed consent, in
accordance with federal and institutional guidelines.
Treatment
Patients received paclitaxel intravenously at 80 mg/m2 once per week
for 16 weeks, with the addition of trastuzumab (TH), lapatinib (TL), or both
(THL). One experimental arm (ie, THL) included all three drugs; the control
arm included TH; the other experimental arm (TL) substituted lapatinib for
trastuzumab. Trastuzumab was administered intravenously with a loading
dose of 4 mg/kg in week 1 and a dose of 2 mg/kg afterward. Lapatinib was
administered orally at 1,500 mg per day alone or 1,000 mg per day when
administered concurrently with trastuzumab. Because of emerging data from
several trials regarding excessive diarrhea, lapatinib was reduced from 1,000
to 750 mg in the THL arm in April 2010, after 34 patients were accrued.
Left ventricular ejection fraction was measured every 8 weeks during
therapy. Drug toxicities were assessed and managed using protocol-
directed dose interruptions and dose reductions.
Surgery was required within 42 days of last dose. Sentinel lymphade-
nectomy was permitted before or after neoadjuvant therapy. Other elements of
postneoadjuvant therapy management, such as axillary dissection in the event
of positive sentinel lymph nodes, tumor-free surgical margins, and radiation
therapy for appropriate clinical circumstances, were specified by the protocol.
Protocol-defined therapy ended at surgery. Postsurgery, patients were
recommended to receive adjuvant chemotherapy with doxorubicin 60 mg/
m2 plus cyclophosphamide 600 mg/m2 administered every 14 to 21 days
for four cycles and 36 additional weeks of trastuzumab. Endocrine therapy
was recommended for patients with estrogen receptor (ER)– or proges-
terone receptor–positive tumors. Patients are being observed for locore-
gional and distant recurrence for up to 10 years from registration.
Tumor Genomic Analyses
All enrolled patients consented to undergo four pretreatment 16-gauge
core biopsies using prefabricated collection and shipping kits: two immediately
placed into RNA stabilization product (RNALater, Qiagen, Hilden, Germany)
and two placed into 10% neutral buffered formalin. They were shipped to the
CALGB Pathology Coordinating Office for distribution to approved labo-
ratories. Samples from the surgical specimen were requested but optional.
Genomic analyses and comparison of pretreatment and post-treatment
tissues are detailed in the Appendix (online only) and used predetermined
RNA-based signatures.18-23 Gene expression profiles were generated by
mRNAseq using an Illumina HiSeq 2000 (San Diego, CA).24 Six-level subtype
classification (basal-like, luminal A, luminal B, HER2 enriched, Claudin low,
and normal-like) involved a two-step normalization process using data from
The Cancer Genome Atlas. Other gene expression signatures related to HER2
signaling and response to therapy that were tested included proliferation,25
fibroblasts,19 HER2 amplicon genes,19 epidermal growth factor receptor
signaling,20 ER signaling,26 p53 mutation,27 KRAS amplicon,21 PI3K path-
way,22 hypoxia/vascular endothelial growth factor,23 five signatures of
immune-cell infiltration (immunoglobulin G [IgG], B cells, T cells, CD8, and
immune cells),18,19 and correlation with the HER2-enriched centroid.25
Data Analysis and Interpretation
Patients were initially randomly assigned with equal probability to the
three study arms. Randomization was stratified by hormone receptor status
(ER or progesterone receptor positive v both negative) and pretreatment
clinical stage (II v III). In July 2011, based on reports of inferiority and greater
toxicity of lapatinib-only regimens, the TL armwas closed; accrual continued
to the THL and TH arms.
The primary end point was pCR in the breast, defined as the absence of
residual invasive carcinoma. A one-df x2 test was used for separate pairwise
pCR comparisons between TH and each experimental arm; exact binomial
methods were used for 95%CIs. With 300 patients, the study had 87% power
to detect an increase in pCR from 30% to 50% in each experimental arm
(two-sided a 5 0.05). After closure of the TL arm, target accrual was revised
to 230 patients in the THL and TH arms, with 85% power for the THL versus
TH comparison. Secondary end points included pCR in breast and ipsilateral
axillary lymph nodes (defined as no invasive tumor by hematoxylin and eosin
staining in any lymph node) and adverse events. Patients who did not undergo
surgery were considered non-pCR. Exploratory logistic regression included
an interaction term for arm by hormone receptor status or stage. All analyses
used a modified intent-to-treat approach that included only patients who
began protocol therapy analyzed according to the randomly assigned arm.
pCR rate by intrinsic subtype was the primary correlative objective.
Pearson’s and Cochran-Mantel-Haenszel x2 tests were used to assess the
association of pCR and intrinsic subtype overall and stratified within THL
and TH arms; those within the TL arm are descriptive. Secondary cor-
relative analyses included 15 established signatures reflecting cell cycle,
pathway signaling, and microenvironment, and association with pCR was
considered as a continuous variable in a logistic regression model. Sig-
nificance of univariable tests was considered using a Bonferroni correction
(P , .0033) for multiple comparisons. A multivariable model of genomic
signatures was derived in stepwise fashion by adding terms to a base model
of treatment arm for genomic features and clinical tumor characteristics
that reached nominal significance (LRT P , .1). Relative changes in gene
expression pre- to post-treatment were explored using paired t tests.
This phase III therapeutic trial was monitored at least twice per year by
the data and safety monitoring board, a standing committee composed of
individuals from within and outside the Alliance. Data were collected and
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stored by the CALGB (Alliance) Statistics and Data Center, and quality was
ensured through data review by the Data Center, the study chairperson, and
the surgical co-chairperson. Data collection and statistical analyses were
conducted by the CALGB (Alliance) Statistics and Data Center by Alliance
statisticians using SAS software (version 9.2; SAS Institute, Cary, NC) and R
software (version 3.0.1; https://www.r-project.org). All analyses were based
on the study database frozen on November 1, 2013.
RESULTS
Clinical
Between December 2008 and February 2012, 305 patients were
enrolled, of whom 299 began protocol treatment (Fig 1). Baseline
characteristics were similar across treatment arms (Table 1). Type
and severity of grade $ 3 adverse events differed significantly by
treatment, with more toxicity (particularly diarrhea and rash) and
early discontinuation in the lapatinib-containing arms (Appendix
Table A1, online only). There were no treatment-related deaths or
episodes of symptomatic congestive heart failure.
Of 295 evaluable patients, 139 experienced pCR in the breast:
56% (95% CI, 47% to 65%) in the THL arm versus 46% (95% CI,
37% to 55%) in the TH arm (P 5 .13); the pCR rate in the TL arm
was 32% (95% CI, 22% to 45%; Fig 2). Response did not differ by
treatment arm for hormone receptor–positive tumors, but it did
within the receptor-negative subset; pCR in the THL arm (79%) was
significantly higher than that in the TH control arm (54%; P5 .01);
pCR in the TL arm was the lowest of the arms (37%), with a trend
toward an interaction between receptor status and treatment arm
(P 5 .09). There was no interaction between clinical stage and
treatment (Appendix Tables A2 and A3, online only).
Gene Expression Signatures and Response
Baseline characteristics of the 265 tumors (90%) that underwent
gene expression profiling did not differ from those the overall study
cohort. Intrinsic subtype differed between hormone receptor–
negative and –positive tumors (P, .001; Fig 3A); the largest subset of
receptor-negative tumors was classified as HER2 enriched (56 [51%]
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Fig 1. CONSORT diagram. pCR, pathologic complete response; QC, quality control; Rx, treatment; TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and
lapatinib; TL, paclitaxel plus lapatinib.
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of 109), whereas luminal subtypes predominated among receptor-
positive tumors (129 [83%] of 156). Response varied significantly by
intrinsic subtype (P , .001) and was approximately double among
HER2-enriched (70%) compared with luminal A and B (34% and
36% respectively) tumors, regardless of treatment arm (Fig 3B;
Appendix Tables A2 and A3) or hormone receptor status.
Genomic signatures reflecting low ER signaling, p53 mutation,
high PI3K pathway signaling, high expression of HER2 amplicon
genes, and correlation with the HER2-enriched centroid were sig-
nificantly associated with pCR after correction for multiple testing.
We also examined five published immune-cell signatures,18,19,28
finding that all of these immune signatures were highly correlated
with one another (data not shown), and one (IgG signature18)
remained associated with pCR after correction for multiple testing
(Table 2). In multivariable analysis, treatment arm, intrinsic subtype,
high HER2 amplicon expression, p53 mutation signature, and IgG
immune-cell expression signature were each independently asso-
ciated with pCR; clinical hormone receptor status was not (Table 2;
Appendix Table A4, online only). When considered as continuous
variables, ESR1 and ERBB2 gene expression as determined from the
mRNAseq data was individually highly associated with pCR. In an
exploratory multivariable modeling including these two genes alone
as well as the predetermined signatures, genomic variables remaining
significantly associated with pCR included ESR1, ERBB2, p53 sig-
nature, and IgG signature (Appendix Table A4), whereas intrinsic
subtype as an overall signature, HER2 amplicon signature, and
clinical assays for ER or HER2 were not.
DNA sequencing was successful in 181 (68%) of 265 tumors.
Mutations in PIK3CAwere detected in 36 (20%), including 14 (25%)
of 57 HER2-enriched, four (7%) of 55 luminal A, and 16 (31%) of 51
luminal B tumors; 93% of the mutations were in exons 9 and 20. The
pCR rate was 39% (14 of 36) among tumors with PIK3CAmutations
and 47% (68 of 145) among those with wild-type PIK3CA (P 5 .5).
Residual Disease Biology
Of 144 tumors that had residual disease after treatment, 78
(54%) had successful mRNAseq on matched pre- and post-treatment
tumor samples. This cohort differed from the overall cohort, with
fewer (n 5 36; 27%) HER2-enriched pretreatment tumors (as
expected, given high pCR rates in this subtype) and more (n 5 85;
63%) luminal tumors. Comparison of matched pre- and post-
treatment tumors demonstrated differences in intrinsic subtype.
Excluding 23 normal-like post-treatment samples, the most frequent
post-treatment subtype alteration among the 55 remaining paired
samples was to the luminal A subtype, occurring in 71% (12 of 17) of
luminal B and 67% (six of nine) of HER2-enriched tumors (Appendix
Table A5, online only) and was seen in both hormone receptor–
positive (29 [78%] of 37) and –negative (nine [50%] of 18) tumors.
Other studies have found intrinsic subtype maintained between
samples from the same tumor29 and inmatched tumor andmetastatic
pairs30; neither cold nor warm ischemia significantly affects subtype.31
To study whether this observation was more likely the result of
treatment effect or tumor heterogeneity, we examined expression of
genes implicated in both HER2-targeting response and the luminal A
subtype, which revealed a significant decrease in expression of HER2
(P, .001) and the proliferation geneMKI67 (P, .001) but not in ER
expression, making it less likely to represent a previously undetected
subclone (Appendix Fig A1, online only), although this is speculative.
DISCUSSION
In 2013, the US Food and Drug Administration used pCR advantage
in a neoadjuvant trial as the basis for accelerated approval of
Table 1. Baseline Characteristics of Study Population (N 5 305)
Characteristic
No. (%)
THL Arm
(n 5 117)
TH Arm
(n 5 118)
TL Arm
(n 5 64)
Age, years
Median 48 50 50
Range 24-70 30-75 25-74
Menopausal status
Pre 72 (62) 63 (53) 36 (56)
Post 41 (35) 52 (44) 27 (42)
Missing 4 (3) 3 (3) 1 (2)
Racial or ethnic group
Black 12 (10) 7 (6) 7 (11)
White 94 (80) 96 (81) 48 (75)
Other 11 (9) 15 (13) 9 (14)
ECOG performance status
0 109 (93) 107 (91) 60 (94)
1 5 (4) 9 (8) 3 (5)
Missing 3 (3) 2 (2) 1 (2)
Hormone receptor status
ER positive, PR positive, or both 69 (59) 70 (59) 37 (58)
ER negative and PR negative 48 (41) 48 (41) 27 (42)
Clinical tumor size on physical
examination, cm
Median 4.0 4.0 4.0
Range 1.4-22.0 1.2-15.0 1.1-12.0
Clinical stage
II 80 (68) 80 (68) 47 (73)
III 37 (32) 38 (32) 17 (27)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen
receptor; PR, progesterone receptor; TH, paclitaxel plus trastuzumab; THL,
paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.
THL
TH
TL
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Overall 
(n = 295)
56%
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Fig 2. Pathologic complete response (pCR) rates in breast by treatment arm,
stratified by hormone receptor status. Error bars represent 95% confidence limits.
TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL,
paclitaxel plus lapatinib.
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pertuzumab added to trastuzumab plus chemotherapy in early
HER2-positive breast cancer.6 CALGB 40601 and three other trials
have examined the neoadjuvant addition of lapatinib administered
in a similar fashion.5,7,32 All have demonstrated numerically higher
pCR rates in the dual HER2-targeting arm compared with single
targeting. The results from two trials were statistically significant,5,32
whereas those of two other trials were not, including our study.7
These trials were similar in many respects, although they differed in
design, including whether the regimen included a single chemo-
therapy drug or several drugs and the duration of the chemotherapy
plus HER2-targeting regimen. The absolute pCR rates varied across
these trials, including a relatively unexpectedly high pCR rate in the
control arm of our trial of 46% (Appendix Table A6, online only). In
CALGB 40601, the addition of lapatinib to 16 weeks of treatment
with trastuzumab and paclitaxel resulted in a numeric increase in the
pCR rate that did not reach statistical significance. There was no
effect in hormone receptor–positive tumors, but there was a stat-
istically significant increase in pCR in hormone receptor–negative,
HER2-positive tumors. Response to therapy was associated with a
number of biologic variables, including tumor molecular subtype
as well as microenvironmental factors such as immune-cell gene
expression. These biomarker associations have clear implications for
how HER2-positive disease is viewed and need to be validated in
independent data sets or a prospective trial.
This study suggests that biologic heterogeneity within HER2-
positive breast cancer plays an important role in determining response
to treatment. For each of the treatment approaches used in this trial,
pCR was markedly higher among HER2-enriched tumors than
among HER2-positive tumors of any other subtype. Among the
HER2-enriched group, the TH control arm experienced a pCRof 70%
in the breast, which is among the highest pCR rates ever reported in
HER2-positive breast cancer. Intrinsic subtype was more important
than hormone receptor status in predicting pCR; in multivariable
analyses including tumor subtype, hormone receptor status was no
longer significant. We also found that immune-cell gene expression
predicted response to HER2 targeting that was independent of other
clinical and genomic factors; this may provide additional means of
identifying highly responsive tumors. This finding is consistent with
reports that tumor-infiltrating lymphocytes are prognostic and pre-
dictive in HER2-positive breast cancer.15,33-36 Low B-cell receptor
diversity in these tumors suggests that this is an antigen-specific
response.18 Expression of the HER2 amplicon genes retained inde-
pendent predictive value for pCR even after controlling for the HER2-
enriched subtype, suggesting, as others have,10 that variable HER2
expression within other subtypes influences response. Within this
population of clinically HER2-positive breast cancer, dominated by
the luminal and HER2-enriched subtypes, we controlled for clinical
ER status, which by itself was not a significant factor for predicting
B
A
pC
R 
Ra
te
 (%
)
100
80
60
40
20
0
HER2-E
(n = 82)
Luminal A
(n = 80)
Luminal B
(n = 80)
70%
34% 36%
HER2-E (n = 82)
Lum A (n = 80)
Lum B (n = 80)
Basal (n = 14)
Claudin-Low (n = 3)
Normal-like (n = 6)
HER2-E (n = 26)
Lum A (n = 54)
Lum B (n = 75)
Basal (n = 1)
Claudin-Low (n = 0)
Normal-like (n = 0)
HER2-E (n = 56)
Lum A (n = 26)
Lum B (n = 5)
Basal (n = 13)
Claudin-Low (n = 3)
Normal-like (n = 6)
3%
2%1%
5%
30%
30%
31%
< 1%
17%
35%
48%
4%
6%
51%
24%
12%
Pretherapy tumors
Hormone receptor positive
Hormone receptor negative Fig 3. Treatment implications of molec-
ular heterogeneity of human epidermal
growth factor receptor 2 (HER2) –positive
breast cancer. (A) Intrinsic subtype overall
and by hormone receptor status among
study population of clinically HER2-positive
tumors, demonstrating that intrinsic
subtype differed between hormone
receptor–negative and –positive tumors
(P , .001). (B) Pathologic complete
response (pCR) rates by intrinsic subtype,
demonstrating significant variation by
intrinsic subtype (P , .001). Uncommon
subtypes not shown. HER2-E, HER2
enriched; Lum, luminal.
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pCR.However, we also evaluated the quantitative expression of ESR1
mRNA and ERBB2 mRNA from our mRNAseq data treated as
continuous variables, alone and in a multivariable analysis; after
adjusting for the mRNA expression of these two genes, the cate-
gorical intrinsic subtype distinction was no longer a significant
independent predictor of pCR. We note that all of these multi-
variable analyses should be considered exploratory, including the
ESR1 and ERBB2mRNAvariables that have never to our knowledge
been measured in this way before (ie, mRNAseq), but are
encouraging and suggest that additional studies with larger sample
sizes will be needed for full evaluation. In addition, if variability in
pCR based on tumor and microenvironment factors translates into
differences in long-term outcome, upfront assessment of these
parameters may be critical.
The distribution of molecular subtypes of residual disease dif-
fered from that of untreated tumors. Under the selective pressure of
combined HER2 targeting and chemotherapy, a high proportion of
tumors that were not eradicated demonstrated the luminal A subtype,
which is characterized by lower expression of proliferation-related
genes and high expression of hormone receptor signaling–related
genes. Whether this reflects stromal alterations, tumor reprogram-
ming, intratumoral heterogeneity, decreased proliferation, and/or
decreased HER2 or other specific pathway signaling cannot be ade-
quately addressed here. We did see highly significant effects on both
HER2 mRNA levels and proliferation gene expression in post-
treatment tumors, but no effect on ER expression. The luminal A
profile is heavily influenced by ER signaling, so this suggests a specific
treatment effect rather than unmasking of a luminal A subclone,
although this requires further study. Neither the treatment implica-
tions of altered biology in post-treatment tumors nor whether these
changes persist over time are known, and this should not be used to
make treatment decisions.
This trial demonstrates the benefits of the neoadjuvant research
approach in terms of size, speed, and capacity to achieve both clinical
and scientific findings. Nonetheless, there are clear limitations.
AlthoughCALGB40601will collect long-termoutcomes of relapse-free
and overall survival, it was not designed or powered for these secondary
end points. Although the subtype-specific and genomic profiling
analyses are intriguing, a far larger prospective trial is needed to evaluate
dual versus single HER2 targeting or any specific drug combination
within individual subtypes. For this reason, a pooled analysis of
molecular plus clinical data from additional large randomized trials is
in development. Although the intrinsic subtypes of breast cancer are
increasingly familiar to practicing clinicians, additional studies are
needed to clarify their role in response to HER2 targeting, as well as to
examine potential interactions with antitumor immunity.
HER2-targeted drugs are among the most expensive cancer
drugs. Trastuzumab-based regimens often exceed $5,000 per month,
and dual therapy regimens can exceed $10,000 per month. Patients
with stage I to III breast cancers receive 1 year of HER2 targeting, and
treatment is generally lifelong for metastatic disease.37 Optimizing the
selection of HER2-targeted regimens by identifying subpopulations of
patients with HER2-positive disease who need more or less therapy
could be cost effective and would spare some patients unnecessary
exposure to ineffective treatments. We found substantial molecular
heterogeneity of HER2-positive breast cancer that was strongly
associated with variable treatment effect regardless of drug regimen,
which supports a new generation of studies exploring the importance
of intrinsic subtype as well as other tumor and microenvironmental
variables in HER-positive disease and the implication of biologic shift
in response to therapy.
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Table 2. Predictors of pCR
Variable
Univariable Model
OR 95% CI P*
Treatment arm .0392
THL v TH 1.39 0.81 to 2.41
TL v TH 0.59 0.3 to 1.15
Intrinsic subtype† , .001
Luminal A v HER2-E 0.22 0.11 to 0.43
Basal v HER2-E 0.24 0.07 to 0.78
Luminal B v HER2-E 0.25 0.13 to 0.48
Normal v HER2-E 0.44 0.08 to 2.51
Gene expression signature
p53 mutation 2.4 1.69 to 3.5 , .001
IgG 1.65 1.3 to 2.12 , .001
HER2 amplicon 1.54 1.23 to 1.93 , .001
HER2-E correlation 1.98 1.50 to 2.68 , .001
ER signaling 0.47 0.33 to 0.66 , .001
B cell 1.49 1.18 to 1.90 , .001
PI3K signaling 1.72 1.25 to 2.41 , .001
NOTE. Variables that remained significantly associated with pCR after adjusting
for multiple comparisons are shown. Full list of variables and nominal and
adjusted ORs from multivariable logistic regression models are included in
Appendix Table A3 (online only).
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor
receptor 2; HER2-E, HER2 enriched; IgG, immunoglobulin G; OR, odds ratio;
pCR, pathologic complete response; PI3K, phosphatidylinositol 3-kinase; TH,
paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL,
paclitaxel plus lapatinib.
*Derived from likelihood ratio test for each variable in logistic regression
model.
†Intrinsic subtypewas evaluated as six-level factor (five df) in logistic regression
models; zero of three Claudin-low samples achieved pCR, so CIs around OR of
zero were not estimable.
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GLOSSARY TERMS
genomic signatures: the expression of a set of genes in a biologic
sample (eg, blood, tissue) using microarray technology.
HER2neu: (human epidermal growth factor receptor 2) also called
ErbB2. HER2neu belongs to the epidermal growth factor receptor
(EGFR) family and is overexpressed in several solid tumors. Like
EGFR, it is a tyrosine kinase receptor whose activation leads to
proliferative signals within the cells. On activation, the human
epidermal growth factor family of receptors are known to form
homodimers and heterodimers, each with a distinct signaling activity.
Because HER2 is the preferred dimerization partner when hetero-
dimers are formed, it is important for signaling through ligands
specific for any members of the family. It is typically overexpressed in
several epithelial tumors.
intrinsic subtype: a subset of tumors that share similarities in their
gene expression profile. Subtypes are identified by unsupervised analysis
of gene expression.
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Appendix
Methods
All of the RNA sequencing (RNAseq) and gene expression analyses were performed in the Genomics Core High Throughput
Sequencing Facility and analyzed by the University of North Carolina Lineberger Comprehensive Cancer Center Bioinformatics
Core at the University of North Carolina.
Intrinsic Subtyping
Gene-level abundances were estimated using the RNAseq by expectation maximization algorithm and then normalized within
sample to the upper quartile of total reads, as previously described.24 For the breast tumors in Cancer and Leukemia Group B (CALGB)
40601, the intrinsic subtyping classifications were performed through a two-step normalization process with a series of 728 breast tumors
from The Cancer Genome Atlas (TCGA) project (Nature 490:61-70, 2012). The mRNA sequencing data are posted at the TCGA data
portal (https://tcga-data.nci.nih.gov/tcga). Briefly, an adjustment was first made to account for differences in the clinically defined human
epidermal growth factor receptor 2 (HER2) –positive populations present in the two data sets by adjusting pretreatment CALGB 40601
samples to clinical HER2-positive TCGA cases. Then, the CALGB data were normalized to the TCGA-derived RNAseq correction factor;
this stepwas needed to adjust RNAseq data to a subset of the datawith the proportion of estrogen receptor (ER) –positive and ER-negative
samples similar to the training data sets for PAM5025 and Claudin-low (Prat A, et al: Breast Cancer Res 12:R68, 2010) predictors.
Normalization and Intrinsic Subtyping
The goal of normalization was to correct bias that may have resulted from technical factors independent of the patient cohort
differences. In the absence of controls, differences in gene-level summary measures (means or medians) may be used to estimate
bias in relative expression measures. This method assumes that the same or similar population was sampled by both technologies.
For CALGB 40601, all tumors were classified as HER2 positive by clinical assay, and the gene expression data set was derived
from 265 pretreatment and 55 matched post-treatment samples (Fig 1). For the TCGA data, there were 115 HER2-positive tumors
defined by clinical assay, comprising 16% (115 of 728) of the TCGA population. To avoid possible confounding of treatment effect
on gene expression patterns, the CALGB-to-TCGA cohort adjustment factor for each gene was calculated by taking the difference in
gene summary measures (median) between the 271 pretreatment CALGB 40601 samples and the 115 clinical HER2-positive TCGA
samples. For each CALGB 40601 tumor sample, the gene expression estimates were adjusted by subtracting each of the adjustment
factors from its corresponding gene measurement. As shown in the principal component analysis plots of all genes, there was a good
general overlap between the two data sets after this correction.
The intrinsic subtyping was then performed using the published PAM50 classifier25 and Claudin-low predictor (Prat A, et al: Breast
Cancer Res 12:R68, 2010). The training sets used for both PAM50 andClaudin-low predictors were derived frommicroarrays. In addition,
breast tumors with ER-positive status comprised 50% of the training data sets, so it was also important to normalize the CALGB 40601
data to a subset of TCGAdata balanced for ER status, whichwe called our TCGA-derived RNAseq correction factor. TCGAdata were first
subsampled for a set of cases that was 50%ERpositive tomatch the ERdistribution of the PAM50 training set; this subset contained all 157
ER-negative and another randomly selected 157 ER-positive tumors. The median gene expression for the genes used in PAM50 and
Claudin-low predictors was calculated, and the CALGB 40601 data were then adjusted to this median, followed by intrinsic subtyping.
Principal component analysis plots illustrated a good general overlap between the CALGB 40601 and PAM50 training data sets.
Gene Expression Signatures
Gene expression signatures reflecting pathways implicated in therapeutic sensitivitywere investigated in this data set. Using the combined
normalized data set with the TCGAdata, we applied 15 signatures to the data set in a manner consistent with their derivation. For signatures
with homogeneous expression across genes, we used the median value from all genes; this included the five immune signatures, fibroblast,
hypoxia or vascular endothelial growth factor, HER1, KRAS amplicon, HER2 amplicon, and phosphatidylinositol 3-kinase signature.18-23
Three of the signatures were correlated with predetermined gene centroids, including ER signaling,26 p53 mutation,27 and
HER2 enriched.25 For the 11-gene proliferation signature,25 we used the mean value of the genes, as is consistent with the output
from the PAM50 algorithm.
Participating Institutions
The following institutions participated in this study: Bay Area Tumor Institute Community Clinical Oncology Program (CCOP),
Oakland, CA, Jon MGrief, MD; Cancer Centers of the Carolinas, Greenville, SC, Jeffrey K. Giguere, MD (supported by National Cancer
Institute [NCI] Grant No. CA29165); Christiana Care Health Services CCOP,Wilmington, DE, Stephen Grubbs,MD (supported by NCI
Grant No. CA45418); DartmouthMedical School–Norris Cotton Cancer Center, Lebanon, NH, Konstantin Dragnev, MD (supported by
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NCI Grant No. CA04326); Dana-Farber Cancer Institute, Boston, MA, Harold J. Burstein, MD, PhD (supported by NCI Grant No.
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Sloan-Kettering Cancer Center, New York, NY, Clifford A. Hudis, MD (supported by NCI Grant No. CA77651); Mount Sinai Medical
Center, Miami, FL, Michael A. Schwartz, MD (supported by NCI Grant No. CA45564); Mount Sinai School of Medicine, New York, NY,
Lewis R. Silverman, MD (supported by NCI Grant No. CA04457); Nevada Cancer Research Foundation CCOP, Las Vegas, NV, John A.
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Table A1. Reasons for Patient Protocol Treatment Discontinuation and Incidence of Selected Grade $ 3 AEs by Arm
Treatment Status
No. (%)
THL Arm TH Arm TL Arm
Began neoadjuvant treatment 117 (100) 118 (100) 64 (100)
Completed per protocol 100 (85) 108 (92) 41 (64)
Ended for toxicity 9 (8) 1 (1) 12 (19)
Ended for progression 2 (2) 2 (2) 0 (0)
Ended for other reason 6 (5) 7 (6) 11 (17)
Patients with delayed doses 82 (70) 34 (29) 53 (83)
Paclitaxel 39 (33) 32 (27) 33 (52)
Trastuzumab 20 (17) 25 (21) NA
Lapatinib 73 (62) NA 40 (63)
AEs*
Neutrophils† 8 (7) 2 (2) 8 (12)
Rash‡ 16 (14) 2 (2) 10 (15)
Diarrhea‡ 25 (22) 2 (2) 14 (21)
Febrile neutropenia 0 (0) 0 (0) 1 (2)
ALT† 6 (5) 1 (1) 3 (5)
AST† 4 (4) 0 (0) 3 (5)
Sensory neuropathy† 11 (10) 4 (3) 3 (5)
Thrombosis 1 (1) 0 (0) 0 (0)
Hypokalemia§ 7 (6) 0 (0) 1 (2)
Abbreviations: AE, adverse event; NA, not applicable; TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.
*Comparison between THL and TH arms.
†P $ .10 but , .14.
‡P # .001.
§P 5 .021.
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Table A2. pCR Rates by Hormone Receptor Status and Stage
No. (%)
Variable THL Arm TH Arm TL Arm
Breast Only
Overall 116 117 62
pCR 65 (56) 54 (46) 20 (32)
95% CI, % 47 to 65 37 to 55 22 to 45
Hormone receptor positive 69 69 35
pCR 28 (41) 28 (41) 10 (29)
95% CI, % 30 to 52 30 to 52 16 to 45
Hormone receptor negative 47 48 27
pCR 37 (79) 26 (54) 10 (37)
95% CI, % 65 to 88 40 to 67 22 to 56
Stage II 79 79 45
pCR 44 (56) 33 (42) 14 (31)
95% CI, % 45 to 66 32 to 53 20 to 46
Stage III 37 38 17
pCR 21 (57) 21 (55) 6 (35)
95% CI, % 41 to 71 40 to 70 17 to 59
Breast and Axillary Lymph Nodes
Overall 116 117 62
pCR 60 (52) 51 (44) 17 (27)
95% CI, % 43 to 61 35 to 53 18 to 40
Hormone receptor positive 69 69 35
pCR 28 (41) 27 (39) 9 (26)
95% CI, % 30 to 52 28 to 51 14 to 42
Hormone receptor negative 47 48 27
pCR 32 (68) 24 (50) 8 (30)
95% CI, % 54 to 80 36 to 64 16 to 49
Abbreviations: pCR, pathologic complete response; TH, paclitaxel plus trastuzumab; THL, paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.
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Table A3. pCR Rates by Intrinsic Subtype
No. (%)
Variable Overall (n 5 265) THL (n 5 103) TH (n 5 104) TL (n 5 58)
Breast Only
Basal-like 14 7 4 3
pCR 5 (36) 4 (57) 0 (0) 1 (33)
95% CI, % 11 to 61 20 to 94 NA 0 to 87
Claudin low 3 1 1 1
pCR 0 (0) 0 (0) 0 (0) 0 (0)
95% CI, % NA NA NA NA
HER2 enriched 82 35 24 23
pCR 57 (70) 28 (80) 17 (71) 12 (52)
95% CI, % 60 to 79 67 to 93 53 to 89 32 to 73
Luminal A 80 30 39 11
pCR 27 (34) 11 (37) 15 (38) 1 (9)
95% CI, % 24 to 44 19 to 54 23 to 54 0 to 26
Luminal B 80 30 32 18
pCR 29 (36) 12 (40) 13 (41) 4 (22)
95% CI, % 26 to 47 22 to 58 24 to 58 3 to 41
Normal-like 6 0 4 2
pCR 3 (50) NA 2 (50) 1 (50)
95% CI, % 10 to 90 NA 1 to 99 1 to 100
Breast and Axilla
Basal-like 14 7 4 3
pCR 0 0 0 0
95% CI, % NA NA NA NA
Claudin low 3 1 1 1
pCR 0 (0) 0 (0) 0 (0) 0 (0)
95% CI, % NA NA NA NA
HER2 enriched 82 35 24 23
pCR 54 (66) 28 (80) 15 (63) 11 (48)
95% CI, % 56 to 76 67 to 93 43 to 82 27 to 68
Luminal A 80 30 39 11
pCR 27 (34) 11 (37) 15 (38) 1 (9)
95% CI, % 23 to 44 19 to 54 23 to 54 0 to 26
Luminal B 80 30 32 18
pCR 27 (34) 12 (40) 12 (38) 3 (17)
95% CI, % 23 to 44 22 to 58 21 to 54 0 to 34
Normal-like 6 0 4 2
pCR 3 (50) NA 2 (50) 1 (50)
95% CI, % 10 to 90 NA 1 to 99 1 to 100
Abbreviations: HER2, human epidermal growth factor receptor 2; NA, not applicable; pCR, pathologic complete response; TH, paclitaxel plus trastuzumab; THL,
paclitaxel, trastuzumab, and lapatinib; TL, paclitaxel plus lapatinib.
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Table A5. Classification of Samples Post-Treatment
Pretreatment Subtype
No. (%)
pCR
Residual Disease Post-Treatment Subtype
HER2 Enriched Luminal A Luminal B Basal-Like Claudin Low Normal-Like NA*
HER2 enriched (n 5 82) 57 (70) 3 (4) 6 (7) 0 0 0 3 (4) 13 (16)
Luminal A (n 5 80) 27 (34) 3 (4) 20 (25) 1 (1) 0 0 7 (9) 22 (28)
Luminal B (n 5 80) 29 (36) 0 12 (15) 3 (4) 0 2 (3) 9 (11) 25 (31)
Basal-like (n 5 14) 5 (36) 0 0 0 3 (21) 0 1 (7) 5 (36)
Claudin low (n 5 3) 0 1 (33) 0 0 0 1 (33) 1 (33) 0
Normal-like (n 5 6) 3 (50) 0 0 0 0 0 2 (33) 1 (16)
NOTE. Pretreatment samples with intrinsic subtype information (n5 265) were compared with post-treatment intrinsic subtype for samples with residual disease. Main
change with treatment seen in these paired samples was to luminal A phenotype, confirming that biology of residual disease differs from that of treatment-naive tumors.
Abbreviations: HER2, human epidermal growth factor receptor 2; NA, not available; pCR, pathologic complete response.
*Lack of consent for post-treatment sample, too little RNA for RNA sequencing, or RNA sequencing failed.
Table A4. All Variables Considered in Univariable and Multivariable Logistic Regression Modeling of Predictors of pCR
Variable
Univariable Model
Multivariable
Model One* Model Two†
OR 95% CI P OR 95% CI P‡ OR 95% CI P‡
Treatment arm .0392 .0077 .0114
THL v TH 1.39 0.81 to 2.41 1.43 0.76 to 2.71 1.5 0.8 to 2.85
TL v TH 0.59 0.30 to 1.15 0.43 0.19 to 0.93 0.48 0.21 to 1.03
Hormone receptor§ 2.17 1.33 to 3.59 , .001 NC NS
Clinical stage II v III 0.67 0.40 to 1.13 .6548 NC NS
Intrinsic subtypek , .001 .0264
Luminal A v HER2-E 0.22 0.11 to 0.43 0.61 0.22 to 1.66 NS
Basal v HER2-E 0.24 0.07 to 0.78 0.24 0.06 to 0.90 NS
Luminal B v HER2-E 0.25 0.13 to 0.48 0.39 0.18 to 0.81 NS
Normal v HER2-E 0.44 0.08 to 2.51 1.66 0.21 to 14.02 NS
Gene expression¶
HER2 2.2 1.68 to 2.93 , .001 NC 1.68 1.25 to 2.28 , .001
ESR1 0.54 0.43 to 0.67 , .001 NC 0.71 0.54 to 0.93 .0139
Gene expression signature
p53 mutation 2.40 1.69 to 3.50 , .001 2.06 1.17 to 3.70 .0119 2.33 1.18 to 4.71 .014
IgG 1.65 1.30 to 2.12 , .001 1.54 1.16 to 2.05 .0024 1.43 1.08 to 1.92 .0112
HER2 amplicon 1.54 1.23 to 1.93 , .001 1.35 1.04 to 1.77 .0252 NS
HER2-E correlation 1.98 1.50 to 2.68 , .001 NS NS
ER signaling 0.47 0.33 to 0.66 , .001 NS NS
B cell 1.49 1.18 to 1.90 , .001 NS NS
PI3K signaling 1.72 1.25 to 2.41 , .001 NS NS
T cell 1.39 1.09 to 1.79 .0073 NS NS
HER1 1.50 1.10 to 2.07 .0103 NS NS
CD8 1.37 1.07 to 1.76 .0115 NS NS
Proliferation 1.43 1.07 to 1.93 .0153 NS NS
Immune cell 1.34 1.05 to 1.70 .0161 NS NS
Hypoxia/VEGF 1.26 0.98 to 1.64 .0717 NS NS
Fibroblast 0.84 0.64 to 1.09 .1852 NS NS
KRAS amplicon 1.11 0.87 to 1.43 .4144 NS NS
Abbreviations: HER2, human epidermal growth factor receptor 2; HER2-E, HER2 enriched; IgG, immunoglobulin G; NC, not considered; NS, not selected; OR, odds ratio;
pCR, pathologic complete response; PI3K, phosphatidylinositol 3-kinase.
*Using preplanned genomic signatures.
†Using same as model one, including clinical factors and with ESR1 and ERBB2 gene expression considered as continuous variables.
‡Derived from likelihood ratio test for each variable in logistic regression model.
§ER and progesterone receptor negative versus either receptor positive.
kIntrinsic subtype was evaluated as six-level factor (five df) in logistic regression models; zero of three Claudin-low samples achieved pCR, so CIs around OR of zero
were not estimable.
¶mRNA expression levels of ESR1 and HER2 determined by mRNA sequencing and treated as continuous variables.
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Table A6. Randomized Neoadjuvant Studies in HER2-Positive Disease Testing Dual HER2 Targeting (v single anti-HER2 drug) in Combination
With Chemotherapy
Study
No. of
Patients Chemotherapy HER2-Targeting Drug
HER2-Targeting
Duration (weeks)
pCR in
Breast (%)
C40601 117 Paclitaxel Trastuzumab 16 46
118 Paclitaxel Trastuzumab 1 lapatinib 16 56
NeoSPHERE5,6 107 Docetaxel Trastuzumab 12 29
107 Docetaxel Trastuzumab 1 pertuzumab 12 46*
107 None Trastuzumab 1 pertuzumab 12 17
B-418 176 AC then paclitaxel Trastuzumab 16 53
165 AC then paclitaxel Trastuzumab 1 pertuzumab 62
NeoALTTO2 149 Paclitaxel Trastuzumab 18 30
152 Paclitaxel Trastuzumab 1 lapatinib (12 with chemotherapy) 51*
CHER-LOB32 36 Paclitaxel then FEC Trastuzumab 26 25
Paclitaxel then FEC Lapatinib 26 26
Paclitaxel then FEC Trastuzumab 1 lapatinib 26 47*
Abbreviations: AC, doxorubicin plus cyclophosphamide; CHER-LOB, Chemotherapy Plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer;
FEC, fluorouracil, epirubicin, and cyclophosphamide; HER2, human epidermal growth factor receptor 2; NeoALLTO, Neoadjuvant Lapatinib and/or Trastuzumab
Treatment Optimisation; NeoSPHERE, Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation; pCR, pathologic complete response.
*Statistically significant increase in pCR according to trial prespecifications. Of note, CHER-LOB (Chemotherapy, Herceptin and Lapatinib in Operable Breast Cancer)
only reported pCR in breast and axillary lymph nodes (in breast not reported).
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Fig A1. Expression of target genes HER2 (ERBB2), estrogen receptor (ESR1), and proliferation gene Ki67 (MKI67) with treatment among 55 tumors with paired
pretherapy and residual disease samples, demonstrating significant decrease in human epidermal growth factor receptor 2 and proliferation gene expression, but no
change in estrogen receptor expression. Normal breast gene expression is provided to illustrate baseline expression patterns.
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